Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors

High-dose methylprednisolone (HDMP) with or without anti-CD20 antibody treatment in the pre B-cell receptor inhibitor (BCRi) era was used as potential salvage therapy for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (r/r CLL/SLL) patients bearing the 17p deletion. Outc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in medical sciences 2020-09, Vol.65 (2), p.371-377
Hauptverfasser:	Puła, Bartosz, Długosz-Danecka, Monika, Salomon-Perzyński, Aleksander, Szymczyk, Agnieszka, Subocz, Edyta, Budziszewska, Bożena Katarzyna, Rybka, Justyna, Gil, Lidia, Waszczuk-Gajda, Anna, Iskierka-Jażdżewska, Elżbieta, Zaucha, Jan M., Osowiecki, Michał, Piszczek, Weronika, Steckiewicz, Paweł, Szukalski, Łukasz, Hus, Marek, Lech-Marańda, Ewa, Jurczak, Wojciech, Jamroziak, Krzysztof
Format:	Artikel
Sprache:	eng
Schlagworte:	B-cell receptor inhibitors Chronic lymphocytic leukemia High-dose methylprednisolone Ibrutinib Idelalisib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	High-dose methylprednisolone (HDMP) with or without anti-CD20 antibody treatment in the pre B-cell receptor inhibitor (BCRi) era was used as potential salvage therapy for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (r/r CLL/SLL) patients bearing the 17p deletion. Outcomes were compared in retrospect between r/r patients treated with HDMP (n = 20), ibrutinib (n = 39) and idelalisib with rituximab (n = 14). Higher overall response rates were found in those patients undergoing BCRi therapy compared to HDMP (79.2% vs. 0%; p
ISSN:	1896-1126 1898-4002
DOI:	10.1016/j.advms.2020.06.002